Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 2016; 388: 248–25716.

Published: 25th August 2016

Authors: Uesaka K, Boku N, Kukutomi A, Okamura Y, Knoishi M, Matsumoto I et al.

Conclusion

Adjuvant chemotherapy with gemcitabine improved overall survival at five years in this study that included 385 patients from 24.4 to 44.1 percent: hazard ratio of mortality 0.57, 95 per cent confidence interval 0.44 to 0.72, P<0.0001.

Pubmed Link

Your comments

0 Comments